FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations
- Trial
- IMpower130
- Drugs
- TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, paclitaxel protein-bound · Taxane, carboplatin · Platinum agent
- Condition
- Thoracic